Are QALYs an appropriate measure for valuing morbidity in acute diseases?
探讨了使用质量调整生命年（QALYs）评估急性疾病干预措施的问题，指出按常规成本效益基准可能无法最大化社会净收益，并提出支付意愿法可能是更合适的替代方法。
In this paper, we examine the problems associated with using quality adjusted life years (QALYs) as the measure of effectiveness to evaluate interventions for acute conditions. We illustrate the way in which using commonly accepted benchmarks for costs per QALY, in order to adopt interventions for acute conditions, might result in decisions that are not consistent with maximizing net societal benefit. We suggest that an alternate methodology, such as willingness to pay, may be more appropriate to make allocation decisions for acute conditions.